Methotrexate Sodium Injection — FDA Drug Shortage

Current — Hospira, Inc., A Pfizer Company

The FDA lists a drug shortage record for Methotrexate Sodium Injection (injection) from Hospira, Inc., A Pfizer Company with status Current. The shortage was first posted on Mar 13, 2023. Reported reason: Other

Shortage details

Status
Current
Company
Hospira, Inc., A Pfizer Company
Package NDC
61703-161-05
Dosage Form
Injection
Presentation
Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) Multiple Dose Vial PREMIERProRx (NDC 61703-161-05)
Initial Posting
Mar 13, 2023

Reason

Other

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.